Otezla was acquired by Amgen for $13.4 billion ... to defend its product by expanding the label of the drug to include mild psoriasis. Last December, it secured FDA approval for the treatment ...

Otezla is currently approved only for moderate-to-severe psoriasis, although Amgen has ongoing trials in milder forms of the disease and analysts have predicted it could become a $2.5 billion product.

Psoriasis treatments that are considered good choices for people over 65 include: Trexall (methotrexate) Soriatane (acitretin) Otezla (apremilast ... severe psoriasis than in those whose disorder is ...

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

About 1 in 3 people with psoriasis who achieved clear skin with biologic drugs still had underlying inflammation that may ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

May 27, 2025 — Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than total body fat, particularly in women. This link ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...